BackMonopar Therapeutics Overview
Monopar Therapeutics Inc

Monopar Therapeutics Target Price

Analysts' average 12-month price target for Monopar Therapeutics is $120.

Get informed when a big investor buys or sells

+ Follow

Share Price

$119.21

Average Target Price

$115.403.2% downside

5 analysts in the last 4 months

High: $125 | Low: $105

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-23UBS$1254.9% upsideOpen
2026-07-22H.C. Wainwright$1254.9% upsideOpen
2026-06-30BTIG$1171.9% downsideOpen
2026-06-29UBS$10511.9% downsideOpen
2026-06-02Piper Sandler$10511.9% downsideOpen
2026-01-09Morgan StanleyMaxwell Skor$1153.5% downsideOpen
2025-11-14Raymond JamesChris Raymond$1233.2% upsideOpen
2025-10-13BarclaysEtzer Darout$1254.9% upsideOpen
2025-10-06Raymond James$14219.1% upsideOpen
2025-10-02Oppenheimer$1153.5% downsideOpen
2025-09-29H.C. Wainwright$10511.9% downsideOpen
2025-09-25Chardan CapitalKeay Nakae$8528.7% downsideOpen
2025-09-25Piper SandlerBiren Amin$9520.3% downsideOpen
2025-09-24BTIG$10412.8% downsideOpen
2025-09-09BTIGJeet Mukherjee$8727% downsideOpen
2025-09-02Raymond James$8032.9% downsideOpen
2025-08-26H.C. Wainwright$7041.3% downsideOpen
2024-11-19UBSJustin Walsh$3769% downsideOpen
2024-11-11H.C. WainwrightSean Lee$2281.5% downsideOpen

Monopar Therapeutics (MNPR) FAQ

Monopar Therapeutics (MNPR) currently reports a target price of $120. Use the charts on this page to explore Monopar Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Monopar Therapeutics is $120, about 3.2% downside from the current share price of $119.21. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $120, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Monopar Therapeutics, and consider following MNPR for alerts when major investors trade the stock.

Monopar Therapeutics is classified in the Healthcare sector. On target price, it currently shows $120. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MNPR with unrelated industries.